Patents by Inventor Emi Hosaka

Emi Hosaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cells with altered fucosylation and producing antibodies therefrom
    Patent number: 8367407
    Abstract: The present invention relates to a cell and mammal in which GDP-mannose 4,6-dehydratase is knocked-out. The cell and mammal are useful for the production of an antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, such as an antibody useful for treating various diseases. The cell and mammal are also useful for the production of a fragment of the antibody, and a fusion protein having the Fc region of the antibody.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: February 5, 2013
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Antibody composition-producing cell
    Patent number: 8329443
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: December 11, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF
    Publication number: 20120177643
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Application
    Filed: March 23, 2012
    Publication date: July 12, 2012
    Applicant: Kyowa Hakko Kirin Co., LTD.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • Glycoengineered, recombinant antibody
    Patent number: 8158760
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: April 17, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Human CDR-grafted antibody and antibody fragment thereof
    Patent number: 8143058
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: March 27, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody
    Patent number: 8110195
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody binding to ganglioside GM2, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: February 7, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Motoo Yamasaki, Nobuo Hanai, Emi Hosaka, Kazuya Yamano
  • Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation
    Patent number: 8101185
    Abstract: The present invention relates to a cell for the production of an anti-IL-5 antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: January 24, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Motoo Yamasaki, Nobuo Hanai, Emi Hosaka, Kazuya Yamano
  • Anti-perp antibody
    Patent number: 8093361
    Abstract: The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: January 10, 2012
    Assignees: Kyowa Hakko Kirin Co., Ltd, Japan as represented by President of National Cancer Center
    Inventors: Atsushi Ochiai, Norihiko Shiraishi, Yoko Kato, Toshio Ota, Susume Sekine, Kenya Shitara, Akiko Furuya, So Ohta, Emi Hosaka, Yuka Sasaki
  • Anti-PERP recombinant antibody
    Patent number: 8093362
    Abstract: An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: January 10, 2012
    Assignees: Kyowa Hakko Kirin Co., Ltd., Japan as Represented by President of National Cancer Center
    Inventors: Atsushi Ochiai, Emi Hosaka, Kazuyasu Nakamura, Akiko Furuya, Yuji Ohki
  • Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase
    Patent number: 8067232
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: November 29, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
    Patent number: 8039595
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: October 18, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • ANTIBODY COMPOSITION-PRODUCING CELL
    Publication number: 20110250643
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Application
    Filed: May 6, 2011
    Publication date: October 13, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Yutaka KANDA, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION
    Publication number: 20110059115
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Application
    Filed: June 18, 2010
    Publication date: March 10, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: YUTAKA KANDA, MITSUO SATOH, KAZUYASU NAKAMURA, KAZUHISA UCHIDA, TOYOHIDE SHINKAWA, NAOKO YAMANE, EMI HOSAKA, KAZUYA YAMANO, MOTOO YAMASAKI, NOBUO HANAI
  • HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF
    Publication number: 20110059524
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Application
    Filed: October 13, 2010
    Publication date: March 10, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenya SHITARA, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION
    Publication number: 20110052610
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Application
    Filed: June 18, 2010
    Publication date: March 3, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION
    Publication number: 20110027271
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Application
    Filed: June 16, 2010
    Publication date: February 3, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Yutaka KANDA, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Antibody composition-producing cell in which enzyme expression is inhibited by RNAi
    Patent number: 7846725
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, wherein the expression of GDP-mannose 4,6-dehydrogenase is inhibited by RNA interference.
    Type: Grant
    Filed: April 1, 2008
    Date of Patent: December 7, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Human CDR-grafted antibody and antibody fragment thereof
    Patent number: 7842797
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: November 30, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • METHOD OF MODULATING THE ACTIVITY OF FUNCTIONAL IMMUNE MOLECULES
    Publication number: 20100196371
    Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.
    Type: Application
    Filed: December 23, 2009
    Publication date: August 5, 2010
    Applicant: KYOWA HAKKO KIRIN, LTD.
    Inventors: NOBUO HANAI, KAZUYASU NAKAMURA, EMI HOSAKA, MOTOO YAMASAKI, KAZUHISA UCHIDA, TOYOHIDE SHINKAWA, SUSUMU IMABEPPU, YUTAKA KANDA, NAOKO YAMANE, HIDEHARU ANAZAWA
  • Method of modulating the activity of functional immune molecules to platelet-derived growth factor receptor
    Patent number: 7763246
    Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: July 27, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Nobuo Hanai, Kazuyasu Nakamura, Emi Hosaka, Motoo Yamasaki, Kazuhisa Uchida, Toyohide Shinkawa, Susumu Imabeppu, Yutaka Kanda, Naoko Yamane, Hideharu Anazawa